# PDUFA dates July 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-07

> 176 FDA catalysts are dated in July 2026, including 9 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in July 2026?

PDUFA dates in July 2026: TRUTAKNA (atacicept, VERA) on July 7, 2026; TAXOL® (paclitaxel, CORT) on July 11, 2026; Lifyorli™ (relacorilant, CORT) on July 11, 2026; Revtorpyk (gedatolisib, FTH) on July 17, 2026; SARCLISA® (isatuximab, SNY) on July 23, 2026; furosemide (MNKD) on July 26, 2026; and 3 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-07)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-210351, https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/fda-calendar/2026-07#answer

## PDUFA dates in July 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| July 7, 2026 | Vera Therapeutics, Inc. | VERA | TRUTAKNA (atacicept) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm) |
| July 11, 2026 | CORCEPT THERAPEUTICS INC | CORT | TAXOL® (paclitaxel) | with platinum-resistant ovarian cancer | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm) |
| July 11, 2026 | CORCEPT THERAPEUTICS INC | CORT | Lifyorli™ (relacorilant) | platinum-resistant ovarian cancer | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm) |
| July 17, 2026 | Faeth Therapeutics, Inc. | FTH | Revtorpyk (gedatolisib) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225333/snse-20260331.htm) |
| July 23, 2026 | Sanofi | SNY | SARCLISA® (isatuximab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312526180848/d137048dex992.htm) |
| July 26, 2026 | MANNKIND CORP | MNKD | furosemide |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm) |
| July 26, 2026 | MANNKIND CORP | MNKD |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm) |
| July 29, 2026 | Outlook Therapeutics, Inc. | OTLK |  |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_8k.htm) |
| July 30, 2026 | Viatris Inc | VTRS | INPEFA® (sotagliflozin) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm) |

## All catalysts in July 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 1, 2026 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| July 1, 2026 | [Cobolimab topline data readout](https://sec-api.dev/pdufa/cobolimab) | GSK | Lung Cancer, Non-Small Cell | completed | "NCT04655976 (Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04655976?tab=results)) |
| July 1, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101?tab=results)) |
| July 1, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | withdrawn | "NCT05882877 (A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05882877)) |
| July 1, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Obesity; Overweight | completed | "NCT06603571 (A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-01 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06603571)) |
| July 1, 2026 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| July 2, 2026 | [MP0712 trial start](https://sec-api.dev/pdufa/mp0712) | MOLN |  | completed | "Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326004433/exh_991.htm)) |
| July 2, 2026 | [CAEL-101 topline data readout](https://sec-api.dev/pdufa/cael-101) | AZN | AL Amyloidosis | completed | "NCT04504825 (A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-10 (ACTUAL); Lead Sponsor Alexion Pharmaceuticals, Inc.; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04504825?tab=results)) |
| July 2, 2026 | [Efg ph20 sc primary completion](https://sec-api.dev/pdufa/efg-ph20-sc) | ARGX | Active Idiopathic Inflammatory Myopathy; Myositis; Dermatomyositis | completed | "NCT05523167 (A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-07-02 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05523167)) |
| July 2, 2026 | [Rsvpref vaccine topline data readout](https://sec-api.dev/pdufa/rsvpref-vaccine) | PFE | Respiratory Syncytial Virus | completed | "NCT06325657 (A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06325657?tab=results)) |
| July 2, 2026 | [Awiqli Flextouch (insulin icodec) topline data readout](https://sec-api.dev/pdufa/insulin-icodec) | NVO | Diabetes, Type 2 | completed | "NCT06340854 (A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340854?tab=results)) |
| July 5, 2026 | [Max fresh toothpaste primary completion](https://sec-api.dev/pdufa/max-fresh-toothpaste) | CL | Oral Malodor | completed | "NCT07398378 (Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially Available Regular Fluoride Toothpaste): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-05 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07398378)) |
| July 6, 2026 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Carcinoma; Non-Small-Cell Lung | completed | "NCT05261399 (Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261399)) |
| July 6, 2026 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Overweight; Obesity; Chronic Kidney Disease | completed | "NCT05536804 (A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-06 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05536804)) |
| July 6, 2026 | [AZD2389 topline data readout](https://sec-api.dev/pdufa/azd2389) | AZN | Liver Fibrosis; Hepatic Cirrhosis | completed | "NCT06750276 (A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06750276?tab=results)) |
| July 7, 2026 | [TRUTAKNA (atacicept) PDUFA date](https://sec-api.dev/pdufa/atacicept) | VERA |  | scheduled | "FDA granted Priority Review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm)) |
| July 7, 2026 | [Trutakna (atacicept-vymj) FDA approval](https://sec-api.dev/pdufa/atacicept-vymj) | VERA |  | completed, approved | "Trutakna \| atacicept-vymj \| 7/7/2026 \| To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| July 7, 2026 | [Alpha-1 mp primary completion](https://sec-api.dev/pdufa/alpha-1-mp) | GRFS | Pulmonary Emphysema in Alpha-1 PI Deficiency | completed | "NCT01983241 (Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor Grifols Therapeutics LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01983241)) |
| July 7, 2026 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Lung Cancer | completed | "NCT06194448 (To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06194448)) |
| July 7, 2026 | [XPHOZAH® (tenapanor) primary completion](https://sec-api.dev/pdufa/tenapanor) | ARDX | Irritable Bowel Syndrome With Constipation (IBS-C) | completed | "NCT06553547 (4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-07 (ACTUAL); Lead Sponsor Ardelyx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06553547)) |
| July 8, 2026 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433?tab=results)) |
| July 8, 2026 | [Avexitide primary completion](https://sec-api.dev/pdufa/avexitide) | AMLX | Post Bariatric Hypoglycemia | completed | "NCT06747468 (Avexitide for Treatment of Post-Bariatric Hypoglycemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-08 (ACTUAL); Lead Sponsor Amylyx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747468)) |
| July 9, 2026 | [Sodium Bicarbonate (sodium bicarbonate) FDA approval](https://sec-api.dev/pdufa/bicarbonate) | AMRX |  | completed, approved | "NDA220790 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260709, review_priority STANDARD; sponsor_name AMNEAL; product SODIUM BICARBONATE (SODIUM BICARBONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220790%22)) |
| July 9, 2026 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709xexx991.htm)) |
| July 9, 2026 | [Sarclisa (isatuximab-irfc) FDA approval](https://sec-api.dev/pdufa/isatuximab-irfc) | SNY |  | completed, approved | "BLA761445 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20260709, review_priority STANDARD; sponsor_name SANOFI-AVENTIS U.S. LLC; product SARCLISA ESCENA (ISATUXIMAB-IRFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761445%22)) |
| July 9, 2026 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Hepatocellular Carcinoma | completed | "NCT04039607 (A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04039607)) |
| July 9, 2026 | [Mibavademab primary completion](https://sec-api.dev/pdufa/mibavademab) | REGN | Generalized Lipodystrophy | completed | "NCT06548100 (A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-09 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548100)) |
| July 10, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| July 10, 2026 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Hypereosinophilic Syndrome | completed | "NCT04191304 (A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04191304?tab=results)) |
| July 10, 2026 | [Bivalent bnt162b2 (original/omicron ba.4/ba.5) 3 microgram dose primary completion](https://sec-api.dev/pdufa/bivalent-bnt162b2-original-omicron-ba-4-ba-5-3-microgram-dose) | BNTX | SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 | completed | "NCT05543616 (A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05543616)) |
| July 10, 2026 | [Datopotamab deruxtecan primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-small Cell Lung Cancer | completed | "NCT06564844 (A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564844)) |
| July 10, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06617429 (Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06617429)) |
| July 10, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-194 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 11, 2026 | [TAXOL® (paclitaxel) PDUFA date](https://sec-api.dev/pdufa/paclitaxel) | CORT | with platinum-resistant ovarian cancer | completed, approved | "•New Drug Application - FDA reviewing NDA for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, with a July 11, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| July 11, 2026 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | platinum-resistant ovarian cancer | scheduled | ""Our NDA for relacorilant in platinum-resistant ovarian cancer, which is now bolstered by the final overall survival results from our ROSELLA study, has a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort022426ex991pressrelease.htm)) |
| July 13, 2026 | [Jemperli (dostarlimab) interim data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | stage II/III mismatch repair deficient/microsatellite instability-high | completed, positive | "GSK plc (LSE/NYSE: GSK) today announced positive interim results from the registrational phase II AZUR-1 trial of Jemperli (dostarlimab) in patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426006614/a9768l.htm)) |
| July 13, 2026 | [VERZENIO (abemaciclib) label expansion decision](https://sec-api.dev/pdufa/abemaciclib) | LLY |  | completed, approved | "NDA208716 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260713, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22)) |
| July 13, 2026 | [Bempikibart topline data readout](https://sec-api.dev/pdufa/bempikibart) | QTTB |  | completed, positive | "2026 - Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/d142528dex991.htm)) |
| July 13, 2026 | [EYP-1901 primary completion](https://sec-api.dev/pdufa/eyp-1901) | EYPT | Wet Age Related Macular Degeneration; wAMD | completed | "NCT06668064 (A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-13 (ACTUAL); Lead Sponsor EyePoint Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06668064)) |
| July 14, 2026 | [Revtorpyk (gedatolisib) FDA approval](https://sec-api.dev/pdufa/gedatolisib) | CELC |  | completed, approved | "Revtorpyk \| gedatolisib \| 7/14/2026 \| In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| July 14, 2026 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Eosinophilic Esophagitis | completed | "NCT05583227 (Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583227)) |
| July 14, 2026 | [Alcestobart topline data readout](https://sec-api.dev/pdufa/alcestobart) | ONC | Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | completed | "NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-07-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909904?tab=results)) |
| July 14, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Atrophic Acne Scars | completed | "NCT05995340 (ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995340)) |
| July 14, 2026 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Ulcerative Colitis | completed | "NCT06254950 (A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06254950)) |
| July 14, 2026 | [GSK5784283 primary completion](https://sec-api.dev/pdufa/gsk5784283) | GSK | Asthma | completed | "NCT06748053 (A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06748053)) |
| July 14, 2026 | [Retevmo (selpercatinib) label expansion decision](https://sec-api.dev/pdufa/selpercatinib) | LLY |  | completed, approved | "NDA213246 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260714, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product RETEVMO (SELPERCATINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213246%22)) |
| July 15, 2026 | [Lipfendra (enlicitide decanoate) FDA approval](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | To reduce low-density lipoprotein cholesterol | completed, approved | "Lipfendra \| enlicitide decanoate \| 7/15/2026 \| To reduce low-density lipoprotein cholesterol" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| July 15, 2026 | [Veradermics, Inc topline data readout](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed, positive | "On July 15, 2026, the Company announced positive topline results from Study '207' evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/mane-20260715.htm)) |
| July 15, 2026 | [RT-114 interim data readout](https://sec-api.dev/pdufa/rt-114) | RANI |  | completed, positive | "On July 15, 2026, we announced positive initial data from the single-dose, open-label Phase 1a portion of our ongoing Phase 1 clinical trial of RT-114." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1856725/000119312526453872/rani-20260930.htm)) |
| July 15, 2026 | [Veradermics, Inc topline data readout](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed, positive | "NEW HAVEN, Conn., July 15, 2026 -- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study '207') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in females with mild-to-moderate pattern hair loss." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/exhibit991datarelease1.htm)) |
| July 15, 2026 | [Reboxetine NDA/BLA acceptance](https://sec-api.dev/pdufa/reboxetine) | AXSM | cataplexy in narcolepsy | completed | "On July 15, 2026, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1579428/000119312526304039/axsm-20260715.htm)) |
| July 15, 2026 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma | completed | "NCT05152147 (A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05152147)) |
| July 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | AZN | Generalized Myasthenia Gravis; gMG | delayed | "NCT05644561 (Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05644561)) |
| July 15, 2026 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | completed | "NCT05814627 (Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05814627)) |
| July 2026 | [Namodenoson primary completion](https://sec-api.dev/pdufa/namodenoson) | CANF | Pancreatic Adenocarcinoma; Pancreatic Cancer | delayed | "NCT06387342 (Namodenoson Treatment of Advanced Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07-15 (ESTIMATED); Lead Sponsor Can-Fite BioPharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387342)) |
| July 15, 2026 | [PF-07220060 topline data readout](https://sec-api.dev/pdufa/pf-07220060) | PFE | Breast Cancer | completed | "NCT06465368 (A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-10 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-07-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465368?tab=results)) |
| July 15, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Generalized Anxiety Disorder | completed | "NCT06741228 (A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06741228)) |
| July 15, 2026 | [Sinovac rabies vaccine primary completion](https://sec-api.dev/pdufa/sinovac-rabies-vaccine) | SVA | Rabies (Healthy Volunteers) | completed | "NCT07416110 (Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07416110)) |
| July 16, 2026 | [MP0317 trial start](https://sec-api.dev/pdufa/mp0317) | MOLN | advanced biliary tract carcinoma | completed | "53 LR - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces the dosing of first patients in an investigator-initiated Phase 2 proof-of-concept (POC) study of MP0317 in combination with chemoimmunotherapy in first line treatment for patients with advanced biliary tract carcinoma (TACTIC), also known as cholangiocarcinoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745114/000117184326004758/exh_991.htm)) |
| July 16, 2026 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "Harmony will report full second quarter 2026 financial results and provide a business update on August 4, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716xex99d1.htm)) |
| July 16, 2026 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-2026q2xexhibitx991.htm)) |
| July 16, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695dex991.htm)) |
| July 16, 2026 | [Adlai Nortye Group Ltd. trial start](https://sec-api.dev/companies/anl/catalysts) | ANL |  | completed | "PRESS RELEASE: ADLAI NORTYE ANNOUNCES FIRST PATIENT DOSED IN INTERMITTENT WEEKLY DOSING ARM OF GLOBAL PHASE 1 TRIAL OF PAN-RAS(ON) INHIBITOR AN9025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1944552/000121390026078874/ea029827801ex99-1.htm)) |
| July 16, 2026 | [Adlai Nortye Group Ltd. trial start](https://sec-api.dev/companies/anl/catalysts) | ANL |  | completed | "Adlai Nortye Announces First Patient Dosed in Intermittent Weekly" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1944552/000121390026078874/ea029827801ex99-1.htm)) |
| July 16, 2026 | [FABHALTA® (iptacopan) label expansion decision](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "NDA218276 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20260716, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22)) |
| July 16, 2026 | [TQJ230 primary completion](https://sec-api.dev/pdufa/tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | completed | "NCT04023552 (Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04023552)) |
| July 16, 2026 | [Luspatercept topline data readout](https://sec-api.dev/pdufa/luspatercept) | BMY | Myeloproliferative Disorders; Myelofibrosis; Primary Myelofibrosis | completed | "NCT04717414 (An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-26 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04717414?tab=results)) |
| July 16, 2026 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 | completed | "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06505031?tab=results)) |
| July 16, 2026 | [Batoclimab primary completion](https://sec-api.dev/pdufa/batoclimab) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT07188844 (An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07188844)) |
| July 17, 2026 | [Revtorpyk (gedatolisib) PDUFA date](https://sec-api.dev/pdufa/gedatolisib) | FTH |  | completed, approved | "In particular, Celcuity has now reported positive topline Phase 3 results from both the PIK3CA wild-type cohort and the PIK3CA mutant cohort of its VIKTORIA-1 trial, has its New Drug Application for gedatolisib in HR+/HER2-, PIK3CA wild-type metastatic breast cancer under FDA Priority Review with a Prescription Drug User Fee Act goal date of July 17, 2026, and has announced its intention to file a supplemental New Drug Application for the PIK3CA mutant indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1829802/000119312526225333/snse-20260331.htm)) |
| July 20, 2026 | [Rostudirsen NDA/BLA acceptance](https://sec-api.dev/pdufa/rostudirsen) | DYN | individuals with Duchenne muscular dystrophy | completed | "On July 20, 2026, Dyne Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted for review its biologics license application ("BLA") for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy ("DMD") amenable to exon 51 skipping." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/dyn-20260720.htm)) |
| July 20, 2026 | [Batoclimab 680 milligrams (mg) subcutaneous (sc) weekly primary completion](https://sec-api.dev/pdufa/batoclimab-680-milligrams-mg-subcutaneous-sc-weekly) | IMVT | Chronic Inflammatory Demyelinating Polyneuropathy | withdrawn | "NCT05581199 (To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Immunovant Sciences GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05581199)) |
| July 20, 2026 | [Vanrafia® (atrasentan) topline data readout](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | completed | "NCT05834738 (Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05834738?tab=results)) |
| July 20, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity | completed | "NCT05931380 (A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05931380?tab=results)) |
| July 20, 2026 | [Inaxaplin primary completion](https://sec-api.dev/pdufa/inaxaplin) | VRTX | Proteinuric Kidney Disease | completed | "NCT06794996 (Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06794996)) |
| July 20, 2026 | [Rsvpref3 oa vaccine primary completion](https://sec-api.dev/pdufa/rsvpref3-oa-vaccine) | GSK | Respiratory Syncytial Virus Infections | completed | "NCT07220109 (A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-20 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220109)) |
| July 21, 2026 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000119312526318853/rgen-ex99_1.htm)) |
| July 21, 2026 | [Dexilant Solutab (dexlansoprazole) primary completion](https://sec-api.dev/pdufa/dexlansoprazole) | TAK | Gastroesophageal Reflux Disease (GERD) | completed | "NCT02616302 (A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02616302)) |
| July 21, 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Psoriasis | completed | "NCT04036435 (Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04036435)) |
| July 21, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05147220 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147220)) |
| July 21, 2026 | [Sephience™ (sepiapterin) primary completion](https://sec-api.dev/pdufa/sepiapterin) | PTCT | Phenylketonuria | completed | "NCT05166161 (A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05166161)) |
| July 21, 2026 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | OSA; Overweight or Obesity | completed | "NCT06649045 (A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06649045)) |
| July 21, 2026 | [Briquilimab primary completion](https://sec-api.dev/pdufa/briquilimab) | JSPR | Urticaria Chronic | withdrawn | "NCT06736262 (A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Jasper Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736262)) |
| July 22, 2026 | [Encaleret NDA/BLA acceptance](https://sec-api.dev/pdufa/encaleret) | BBIO | individuals living with autosomal dominant hypocalcemia type 1 | completed | "PALO ALTO, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) for encaleret for the treatment of individuals living with autosomal dominant hypocalcemia type 1 (ADH1)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_ex99-1.htm)) |
| July 22, 2026 | [Zidesamtinib FDA approval](https://sec-api.dev/pdufa/zidesamtinib) | GSK | ROS1-positive NSCLC previously treated | completed, approved | "Following US FDA approval of Jideytro (zidesamtinib) on 22 July 2026, Nuvalent began commercial sales." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009181/a6993a.htm)) |
| July 22, 2026 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports Second Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000023/medp-2026722exx991.htm)) |
| July 22, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05156281 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156281)) |
| July 22, 2026 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Colorectal Cancer (CRC) | completed | "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05198934?tab=results)) |
| July 22, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06101329 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06101329)) |
| July 22, 2026 | [Livtencity (maribavir) primary completion](https://sec-api.dev/pdufa/maribavir) | TAK | Cytomegalovirus (CMV) | completed | "NCT06439342 (A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439342)) |
| July 23, 2026 | [Furosemide FDA approval](https://sec-api.dev/pdufa/furosemide) | MNKD | edema | completed, approved | "On July 23, 2026, the U.S. Food and Drug Administration approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm)) |
| July 23, 2026 | [Ihl-42x: 2.5 mg dronabinol + 125 mg acetazolamide trial start](https://sec-api.dev/pdufa/ihl-42x) | IXHL | obstructive sleep apnea | completed | "Australia and NEW YORK, 23 July, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications, is pleased to announce that participant screening has commenced in the Company's DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea ("OSA")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea029867401ex99-1.htm)) |
| July 23, 2026 | [SARCLISA® (isatuximab) PDUFA date](https://sec-api.dev/pdufa/isatuximab) | SNY |  | scheduled | "The revised target action date for the FDA decision is July 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312526180848/d137048dex992.htm)) |
| July 23, 2026 | [Ivonescimab earnings report](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed | "Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reached in Second Half of 2026 with Interim OS Analyses Planned" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/a2026_prx0723xq22026earn.htm)) |
| July 23, 2026 | [Pf-06838435 (formerly spk-9001) primary completion](https://sec-api.dev/pdufa/pf-06838435-formerly-spk-9001) | PFE | Hemophilia B | withdrawn | "NCT03307980 (Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03307980)) |
| July 23, 2026 | [Dazodalibep primary completion](https://sec-api.dev/pdufa/dazodalibep) | AMGN | Sjogren's Syndrome | completed | "NCT06104124 (A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104124)) |
| July 23, 2026 | [Evo756, dose 1 primary completion](https://sec-api.dev/pdufa/evo756) | EVMN | Atopic Dermatitis | completed | "NCT07150845 (Phase 2b Study of EVO756 in Adults With Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-23 (ACTUAL); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07150845)) |
| July 24, 2026 | [LYTENAVA™ (lytenava) FDA approval](https://sec-api.dev/pdufa/lytenava) | OTLK | wet AMD | completed, approved | "On July 24, 2026, we announced that the FDA approved LYTENAVA for the treatment of wet AMD." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm)) |
| July 24, 2026 | [MVASI® (bevacizumab) FDA approval](https://sec-api.dev/pdufa/bevacizumab) | OTLK | To treat patients with neovascular (wet) age-related macular degeneration | completed, approved | "Lytenava \| bevacizumab-vikg \| 7/24/2026 \| To treat patients with neovascular (wet) age-related macular degeneration" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| July 24, 2026 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-ex99_1.htm)) |
| July 24, 2026 | [AJOVY® (fremanezumab) topline data readout](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110?tab=results)) |
| July 24, 2026 | [Rocatinlimab topline data readout](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Atopic Dermatitis | completed | "NCT05633355 (A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05633355?tab=results)) |
| July 24, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06067230 (A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067230)) |
| July 24, 2026 | [Bnt162b2 (2025/2026 formulation) primary completion](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation) | BNTX | COVID-19; SARS-COV-2 Infection | completed | "NCT07222384 (A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222384)) |
| July 26, 2026 | [Furosemide PDUFA date](https://sec-api.dev/pdufa/furosemide) | MNKD |  | completed, approved | "FDA accepted for review a supplemental New Drug Application (sNDA) for Furoscix ReadyFlow Autoinjector; with a PDUFA target action date of July 26, 2026; if approved, it would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm)) |
| July 26, 2026 | [MANNKIND CORP PDUFA date](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | scheduled | "Furoscix ReadyFlow Autoinjector PDUFA date July 26, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm)) |
| July 27, 2026 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - July 27, 2026 - Champions Oncology, Inc. (Nasdaq: CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828026049822/csbr8-k4302026exhibit991.htm)) |
| July 27, 2026 | [Betovumeline topline data readout](https://sec-api.dev/pdufa/betovumeline) | MPLT | acute exacerbation of schizophrenia | completed, positive | "(Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist (betovumeline) co-formulated with a peripherally acting anticholinergic (fesoterodine), in adults with an acute exacerbation of schizophrenia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526316820/d139086dex992.htm)) |
| July 27, 2026 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000119312526318069/opk-ex99_1.htm)) |
| July 27, 2026 | [GeoVax Labs, Inc. earnings report](https://sec-api.dev/companies/govx/catalysts) | GOVX |  | completed | "GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/832489/000143774926024522/ex_993355.htm)) |
| July 2026 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | AZN | Ovarian Cancer | delayed | "NCT04884360 (D9319C00001- 1L OC Mono Global RCT): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-27 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04884360)) |
| July 27, 2026 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | Pre-Exposure Prophylaxis of HIV Infection | completed | "NCT06101342 (Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06101342)) |
| July 27, 2026 | [GM-2505 primary completion](https://sec-api.dev/pdufa/gm-2505) | ABBV | Major Depressive Disorder | completed | "NCT06236880 (A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236880)) |
| July 28, 2026 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728xex99d1.htm)) |
| July 28, 2026 | [Nimodipine complete response letter (CRL)](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed, complete response letter | "Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036126029837/ef20078866_ex99-1.htm)) |
| July 28, 2026 | [Pemvidutide topline data readout](https://sec-api.dev/pdufa/pemvidutide) | ALT |  | completed, positive | "As noted above, on July 28, 2026, the Company announced the positive topline results from the RECLAIM Phase 2 trial evaluating the 2.4 mg dose of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe AUD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000044/alt-20260728x8k.htm)) |
| July 28, 2026 | [IQVIA HOLDINGS INC. earnings report](https://sec-api.dev/companies/iqv/catalysts) | IQV |  | completed | "IQVIA Reports Second-Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478242/000162828026049923/iqv-q2x2026earningspressre.htm)) |
| July 28, 2026 | [Alkermes plc. earnings report](https://sec-api.dev/companies/alks/catalysts) | ALKS |  | completed | "Alkermes plc Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)) |
| July 28, 2026 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774926024663/ex_992998.htm)) |
| July 28, 2026 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000173043026000031/knsa-20260728xex99d1.htm)) |
| July 28, 2026 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm)) |
| July 28, 2026 | [Gwyn Lo (ethinyl estradiol; norelgestromin) FDA approval](https://sec-api.dev/pdufa/ethinyl-estradiol-norelgestromin) | VTRS |  | completed, approved | "NDA219990 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260728, review_priority STANDARD; sponsor_name VIATRIS SPECIALTY; product GWYN LO (ETHINYL ESTRADIOL; NORELGESTROMIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219990%22)) |
| July 28, 2026 | [CTX-009 topline data readout](https://sec-api.dev/pdufa/ctx-009) | CMPX | Metastatic Colorectal Cancer; Colon Cancer; Rectal Cancer | completed | "NCT05513742 (A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Compass Therapeutics; Results First Posted 2026-07-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05513742?tab=results)) |
| July 29, 2026 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports second quarter 2026 financial results and highlights progress on key programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036126029960/ef20078953_ex99-1.htm)) |
| July 29, 2026 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm)) |
| July 29, 2026 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_8k.htm)) |
| July 29, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm)) |
| July 29, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD earnings report](https://sec-api.dev/companies/teva/catalysts) | TEVA |  | completed | "TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm)) |
| July 29, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/exh_991.htm)) |
| July 29, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong second quarter 2026 results demonstrating progress toward its goal of sustainable revenue growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/exhibit991-q22026pressrele.htm)) |
| July 29, 2026 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559026000105/ex991-q22026.htm)) |
| July 29, 2026 | [AMARIN CORP PLCUK earnings report](https://sec-api.dev/companies/amrn/catalysts) | AMRN |  | completed | "Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/897448/000119312526323841/amrn-ex99_1.htm)) |
| July 29, 2026 | [Deramiocel FDA advisory committee meeting](https://sec-api.dev/pdufa/deramiocel) | CAPR | treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD) | completed, mixed | "On July 29, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125842 from Capricor, Inc. for deramiocel (human allogeneic cardiosphere-derived cells) the treatment of cardiomyopathy in Duchenne muscular dystrophy (DMD)." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-29-2026-meeting-announcement-updated)) |
| July 29, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526323940/dyn-ex99_1.htm)) |
| July 29, 2026 | [SIL204 trial start](https://sec-api.dev/pdufa/sil204) | SLXN |  | completed | "On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer ("LAPC")" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326005216/exhibit_99-1.htm)) |
| July 29, 2026 | [Corcept earnings report](https://sec-api.dev/pdufa/corcept) | CORT |  | completed | "Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort072926ex991pressrelease.htm)) |
| July 29, 2026 | [TAR-200 topline data readout](https://sec-api.dev/pdufa/tar-200) | JNJ | Urinary Bladder Neoplasms | completed | "NCT04640623 (A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-07-03 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-07-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04640623?tab=results)) |
| July 29, 2026 | [LIVMARLI® (maralixibat) primary completion](https://sec-api.dev/pdufa/maralixibat) | MIRM | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | completed | "NCT06553768 (Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-29 (ACTUAL); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06553768)) |
| July 29, 2026 | [Pcs6422 and capecitabine primary completion](https://sec-api.dev/pdufa/pcs6422-and-capecitabine) | PCSA | Breast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancer | withdrawn | "NCT06568692 (A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-29 (ACTUAL); Lead Sponsor Processa Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568692)) |
| July 30, 2026 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "On July 30, 2026, we submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to 11 years who weigh 13 kg to 27 kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| July 30, 2026 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/a2026q2ex991-filing.htm)) |
| July 30, 2026 | [ALNYLAM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/alny/catalysts) | ALNY |  | completed | "Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny2026q2earningsrelease.htm)) |
| July 30, 2026 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (July 30, 2026) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/exhibit991q22026.htm)) |
| July 30, 2026 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-q22026ex991.htm)) |
| July 30, 2026 | [NEUROCRINE BIOSCIENCES INC earnings report](https://sec-api.dev/companies/nbix/catalysts) | NBIX |  | completed | "SAN DIEGO, July 30, 2026 - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/q2-2026xearningsrelease.htm)) |
| July 30, 2026 | [INPEFA® (sotagliflozin) PDUFA date](https://sec-api.dev/pdufa/sotagliflozin) | VTRS |  | scheduled | "the NDA for the Company's investigational low dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol) for contraception was accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a PDUFA goal date of July 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000010/exhibit991-4q25earningsrel.htm)) |
| July 30, 2026 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "2026 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/tm2621593d1_ex99-1.htm)) |
| July 30, 2026 | [Wave Life Sciences, Inc. earnings report](https://sec-api.dev/companies/wve/catalysts) | WVE |  | completed | "Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737dex991.htm)) |
| July 30, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/exhibit991-63026earningspr.htm)) |
| July 30, 2026 | [ANAVEX LIFE SCIENCES CORP. earnings report](https://sec-api.dev/companies/avxl/catalysts) | AVXL |  | completed | "Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1314052/000173112226000988/e7813_ex99-1.htm)) |
| July 30, 2026 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-ex99_1.htm)) |
| July 30, 2026 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879dex991.htm)) |
| July 30, 2026 | [AGIOS PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/agio/catalysts) | AGIO |  | completed | "Agios Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-73026xfyxex991earning.htm)) |
| July 30, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026051051/q220268kex991.htm)) |
| July 30, 2026 | [CRESCENT BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/cbio/catalysts) | CBIO |  | completed | "Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/pressrelease-livefile.htm)) |
| July 30, 2026 | [Evo756, dose 1 trial start](https://sec-api.dev/pdufa/evo756) | EVMN |  | completed | "Palo Alto, Calif., and New York, July 30, 2026 - Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-ex99_1.htm)) |
| July 30, 2026 | [Vericel Corp earnings report](https://sec-api.dev/companies/vcel/catalysts) | VCEL |  | completed | "Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/ex991earningsreleaseq22026.htm)) |
| July 30, 2026 | [TACTI-004 trial start](https://sec-api.dev/pdufa/tacti-004) | IMMP |  | completed | "As previously announced, a proposed investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in early-stage HR+/HER2-negative breast cancer remains on hold pending completion of the root cause analysis related to TACTI-004." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506184/000119312526329120/d178051dex991.htm)) |
| July 30, 2026 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Muscular Atrophy, Spinal | completed | "NCT04729907 (A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04729907)) |
| July 2026 | [Nirmatrelvir primary completion](https://sec-api.dev/pdufa/nirmatrelvir) | PFE | COVID-19 | delayed | "NCT05261139 (EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-07-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05261139)) |
| July 30, 2026 | [Baxfendy (baxdrostat) topline data readout](https://sec-api.dev/pdufa/baxdrostat) | AZN | Uncontrolled Hypertension; Resistant Hypertension | completed | "NCT06034743 (A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06034743?tab=results)) |
| July 30, 2026 | [Mazisotine topline data readout](https://sec-api.dev/pdufa/mazisotine) | LLY | Diabetic Peripheral Neuropathy | completed | "NCT06074562 (A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074562?tab=results)) |
| July 30, 2026 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Crohn's Disease | withdrawn | "NCT06637631 (A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06637631)) |
| July 30, 2026 | [Pemvidutide primary completion](https://sec-api.dev/pdufa/pemvidutide) | ALT | Alcohol Use Disorder (AUD) | completed | "NCT06987513 (RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Altimmune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06987513)) |
| July 30, 2026 | [Vusolimogene oderparepvec FDA advisory committee meeting](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL |  | completed | "On July 30, 2026, the Committee will meet in open session to discuss and make recommendations on Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec. The proposed indication (use) is in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD-1 containing regimen." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-updated)) |
| July 31, 2026 | [Obsidian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/obx/catalysts) | OBX |  | completed | "If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2130606/000119312526330810/d309963dex992.htm)) |
| July 31, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm)) |
| July 31, 2026 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/a06302026ex991.htm)) |
| July 31, 2026 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/d90330dex991.htm)) |
| July 31, 2026 | [GAZYVA® (obinutuzumab) FDA approval](https://sec-api.dev/pdufa/obinutuzumab) | ABBV |  | completed, approved | "•Allergan Aesthetics announced the FDA approved Skinvive by Juvederm as the first hyaluronic acid injectable indicated to reduce neck lines for the improvement of neck appearance in adults over the age of 21." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| July 31, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Second-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| July 31, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm)) |
| July 31, 2026 | [Pivekimab FDA approval](https://sec-api.dev/pdufa/pivekimab) | ABBV |  | completed, approved | "•AbbVie announced the FDA approved Decnupaz (pivekimab sunirine) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive hematologic malignancy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| July 31, 2026 | [Pluvicto (lutetium lu-177 vipivotide tetraxetan) label expansion decision](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan) | NVS |  | completed, approved | "NDA215833 SUPPL-37 (Efficacy): submission_status AP, submission_status_date 20260731, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22)) |
| July 31, 2026 | [Arlocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/arlocabtagene-autoleucel) | BMY | Multiple Myeloma | completed | "NCT06297226 (Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07-31 (ACTUAL); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297226)) |
| July 31, 2026 | [Zimrixby (rituximab-cdxx) FDA approval](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, approved | "BLA761376 ORIG-1: submission_status AP, submission_status_date 20260731, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product ZIMRIXBY (RITUXIMAB-CDXX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761376%22)) |

Other months: https://sec-api.dev/fda-calendar/2026-06 , https://sec-api.dev/fda-calendar/2026-08. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates July 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-07

```bibtex
@misc{secapidev_fda_calendar_2026_07_20261116,
  title        = {PDUFA dates July 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-07}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_07_20261116","title":"PDUFA dates July 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-07","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
